All News

A new chemotherapy drug (alisertib or MLN8237) being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who participated in a phase I study.

Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer Approval Reinforces Amgen Commitment to Personalized Medicine.

Chronically ill patients, who are more likely to require necessary care, should pay less for health insurance, Aaron E. Carroll, a professor of pediatrics at Indiana University School of Medicine, argued in an op-ed for the New York Times.

A new report highlights the ways hospitals can identify and address sources of "avoidable suffering" and ultimately improve the patient experience.

Federally qualified health centers (FQHCs) have increased their EHR adoption by 133% over the past four years, says a report from The Commonwealth Fund, with 93% of FQHCs in possession of an EHR and 85% of these community provider organizations reporting advanced HIT capabilities.

The patient-centered medical home model in Arkansas, which has more than 600 participating providers, helps the state's Medicaid program incentivize quality care instead of paying for volume of services.

A change to provisions in the Affordable Care Act (ACA) would allow insurers to receive federal funding for any financial losses they endured due to the health law.

1.0 Credit - CME/CPE | Expires 4/18/2015

Trials conducted at the Abramson Cancer Center among others have identified the potential of an antimalarial agent, hydroxychloroquine, in stabilizing aggressive cancers.

EU's Committee for Medicinal Products for Human Use (CHMP)supported the use of Gazyvaro based on the phase III CLL11 study, wherein treatment with Gazyvaro (obinutuzumab) plus chlorambucil significantly reduced the risk of disease worsening or death by 86% and increased survival time for previously untreated CLL patients compared to those who received treatment with chlorambucil alone.

Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.

A CMS proposal could extend the deadline for providers to transition to Stage 2 meaningful use of electronic health records (EHRs). Agency officials said they have received extensive feedback from health providers who felt they did not have enough time to efficiently transition their EHR systems.

A research article published in Nature Communications identifies a new mechanism of breast cancer metastasis.

'Encouraging' Period of Stable Disease Suggested in Direct Injection Vaccine Treatment of Pancreatic Cancer. Research from Rutgers Cancer Institute of New Jersey to be presented at the Pancreatic Cancer-focused meeting held by AACR in New Orleans.

Amid strong lobbying by business groups, support is growing to end the Affordable Care Act's employer mandate, a change that would see millions more Americans buying their health insurance through exchanges.

A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.

As part of a contract extension with Tenet Healthcare, Cigna has established a first of its kind quality-based reimbursement agreement.

A CMS ruling would force healthcare providers to enroll in Medicare by June 1, 2015, if they plan to prescribe medications that are paid for by the program. The agency said in a report that changes to Medicare Part D were necessary in order to cut down on inappropriate prescription practices and to improve patient safety.

NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.

CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.

Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.

New Health Resources and Services Administration (HRSA) regulations could limit certain hospitals from participating in the 340B drug discount program.

Health and policy experts are pushing for a system that pays doctors a lump sum for medical care or allows them to share in savings, saying it will save millions of dollars over current fee-for-service payments that can lead to fraud and over-use of medications.

Parents in low-income families were less likely to delay asthma care for their children or avoid taking their children to see a doctor is they had lower vs. higher levels of health insurance cost-sharing.

Combining a novel radioimmunotherapy treatment with gemcitabine presented encouraging results in PDAC patients who had undergone metastasis. The data was presented at a AACR special conference currently being held in New Orleans.

GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.

Few states could claim Obamacare's first enrollment period was smooth-whatever the final numbers-but most will approach their insurance exchanges the same way for the 2015 window. None has asked the Obama administration to take over its marketplace or elected to abandon HealthCare.gov in favor of running its own.

Researchers at Brown University may provide a new early diagnostic test for pancreatic cancer.

Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.